| Trial ID: | L2088 |
| Source ID: | NCT03556631
|
| Associated Drug: |
Live Combined Bifidobacterium And Lactobacillus Tablets
|
| Title: |
Effect of Live Combined Bifidobacterium and Lactobacillus on Glycemic Control and Other Outcomes in Type 1 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 1 Diabetes Mellitus|Probiotics
|
| Interventions: |
DRUG: live combined Bifidobacterium and Lactobacillus Tablets
|
| Outcome Measures: |
Primary: hemoglobin A1c in percentage, analyze the change of hemoglobin A1c between two groups, 3 months | Secondary: weight in kilograms, analyze the change of weight in kilograms between two groups, 3 months
|
| Sponsor/Collaborators: |
Sponsor: Shenzhen People's Hospital
|
| Gender: |
ALL
|
| Age: |
ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
60
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT
|
| Start Date: |
2020-09-01
|
| Completion Date: |
2021-10-30
|
| Results First Posted: |
|
| Last Update Posted: |
2022-08-09
|
| Locations: |
Shenzhen People' S Hospital, Shenzhen, 518020, China
|
| URL: |
https://clinicaltrials.gov/show/NCT03556631
|
